TPOAb和TGAb与女性不孕的相关性研究

目的 探讨抗甲状腺过氧化物酶抗体(TPOAb)和抗甲状腺球蛋白抗体(TGAb)与女性不孕的关系.方法 用电化学发光法检测543例不孕女性血清中的甲状腺抗体(ATA)水平,包括TPOAb和TGAb,并以100例健康育龄妇女为对照,比较两组的TPOAb和TGAb阳性率.结果 研究组的TPOAb总阳性率高于对照组(19.2％比9.0％),两组比较差异有统计学意义(x 2=6.009 42,P＜0.05);研究组与对照组TGAb总阳性率分别为12.5％、7.0％,两组比较差异无统计学意义(x 2=2.500 08,P＞0.05);研究组ATA总阳性(TPOAb和/或TGAb阳性)率高于对照组(24.1％比15.0％),差异有统计学意义(x 2=4.006 72,P＜0.05).结论 TPOAb、TGAb与女性不孕关系密切,两者联合检测有利于女性不孕病因的查找.     

血甲状腺过氧化物酶抗体阳性孕妇妊娠结局分析

目的 通过对孕妇甲状腺功能及甲状腺过氧化物酶抗体(TPOAb)的测定,探讨血TPOAb阳性对孕妇妊娠结局的影响.方法 选取2015年1月至2015年12月来苏州市立医院建卡的250例孕妇作为研究对象,根据TPOAb滴度分为TPOAb阳性组和TPOAb阴性组.比较两组孕妇的血清甲状腺激素水平、妊娠结局和新生儿并发症的发生率.结果 250例患者中,TPOAb阳性者87例,TPOAb阴性组163例,两组甲状腺激素水平差异有统计学意义(P＜0.05).TPOAb阳性组孕妇合并胎儿窘迫11例(12.64％),早产10例(11.49％),其发生率明显高于TPOAb阴性组,差异有统计学意义(P＜0.05).TPOAb阳性组孕妇合并妊娠期糖尿病、妊娠期高血压疾病、胎膜早破的发生率稍高于TPOAb阴性组,差异无统计学意义(P＞0.05).TPOAb阳性组低出生体重儿、新生儿窒息、死胎、新生儿甲减发生率明显高于TPOAb阴性组,差异有统计学意义(P＜0.05).两组胎儿畸形发生率差异无统计学意义(P＞0.05).结论 妊娠期的TPOAb对妊娠期亚临床甲状腺功能减退的诊断和妊娠结局的判断具有一定的意义.     

妊娠妇女甲状腺功能筛查的必要性与策略探讨

目的 探讨妊娠早期孕妇甲状腺过氧化物酶(TPOAb)及促甲状腺激素(TSH)筛查在自身免疫性甲状腺疾病功能紊乱诊断中的临床价值.方法 100例孕妇按TPOAb定性检测结果分为TPOAb阳性组48例和TPOAb阴性组52例,按临床诊断标准分为甲状腺功能紊乱组(A组)50例和非甲状腺功能紊乱组(B组)50例,采用电化学发光法对100例孕妇进行血清TPOAb检测,同时用化学发光法检测TSH.结果 100例孕妇中,TPOAb阳性48例,TPOAb阴性52例.A组TSH水平(8.46±4.47) mlU/L,高于B组的(1.62±0.85) mlU/L(t =0.45,P＜0.05);A组TPOAb水平(97.34±24.73) U/ml,高于B组的(11.28 +4.36)U/ml(t =3.41,P＜0.05);A组TPOAb阳性率(82％)高于B组(14％) (x2 =2.17,P＜0.05).TPOAb阳性组TSH＜ 0.3 U/L或＞ 5.50 U/L发生率为23％,高于TPOAb阴性组的6％(x2=1.42,P＜0.05).结论 TPOAb阳性孕妇甲状腺功能紊乱明显增加,有向亚临床甲状腺功能减退发展的趋势.     

甲状腺功能6项指标联合检测评估甲状腺疾病的价值

目的 探讨甲状腺功能6项指标联合检测评价甲状腺功能及其临床意义.方法 甲状腺疾病患者200例均分为四组:甲状腺功能亢进(A)组、Graves病(B)组、甲状腺功能减退(C)组和桥本甲状腺炎(D)组;另设健康对照组(E组,50例).采用免疫化学发光法检测血清游离三碘甲状腺氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、甲状腺球蛋白抗体(TGAb)、甲状腺过氧化物酶抗体(TPOAb)、促甲状腺受体抗体(TRAb)水平,分析组间差异.结果 A组与B组血清FT3、FT4水平明显高于E组,TSH水平低于E组;C组与D组血清FT3、FT4水平明显低于E组,TSH水平高于E组(P＜0.05);五组FT3、FT4、TSH诊断符合率差异均无统计学意义(P＞0.05).A组、B组、C组、D组患者血清TGAb、TPOAb、TRAb阳性率与E组比较差异有统计学意义(P＜0.05).结论 联合检测FT3、FT4、TSH和TGAb、TPOAb和TRAb在甲状腺疾病的鉴别诊断、治疗及判断预后具有参考价值,可指导临床用药.     

妊娠期甲状腺过氧化物酶抗体与甲状腺球蛋白抗体水平对产科并发症预测价值研究

目的探讨妊娠期甲状腺过氧化物酶抗体(TPOAb)与甲状腺球蛋白抗体(TGAb)水平对产科并发症预测价值。方法选取2017年7月～2018年7月我院收治的孕期保健孕妇400例为研究对象,根据其TPOAb与TGAb检测结果将其分为四组,TPOAb阳性TGAb阴性者为A组,TPOAb阴性TGAb阳性者为B组,TPOAb与TGAb均为阳性者为C组,TPOAb与TGAb均为阴性者为对照组,对各组妊娠中期甲状腺功能、不良妊娠结局、围生儿并发症情况进行比较。结果 C组甲状腺功能异常率、不良妊娠结局发生率均明显高于对照组,差异有统计学意义(P 0.05);四组两两比较围生儿出生时体质量2.5kg、吸入综合征等发生率比较均差异无统计学意义(P 0.05)。结论 TPOAb与TGAb均为阳性的孕妇出现妊娠期甲状腺功能异常及不良妊娠结局的几率均较高,TPOAb与TGAb水平可为不良妊娠结局的预测提供参考。     

血清TSH、TGAb、TPOAb联合超声特征对良恶性甲状腺结节的诊断价值

目的探讨血清TSH、TGAb、TPOAb联合超声特征对甲状腺结节良恶性的诊断价值。方法选取2013年1月~2015年12月的189例甲状腺结节纳入观察,良性100例,恶性89例。对良、恶性组间超声特征及血清学指标进行对照分析。结果实性、形态不规则、边界不清、低回声、纵横比1及微钙化等超声特征在良、恶性组间差异有统计学意义。良、恶性组间TGAb、TPOAb阳性率差异有统计学意义,TSH水平则无显著差异。平行试验显示,甲状腺结节出现3个超声特征和TPOAb阳性或TGAb阳性时,特异性最高(93.0%);序列试验显示,甲状腺结节出现3个超声特征和TGAb、TPOAb均阳性时,特异性高达100%。结论超声检查结合血清TGAb、TPOAb检测在甲状腺结节良恶性鉴别中具有重要应用价值,可在临床借鉴应用。     

甲状腺球蛋白抗体和甲状腺过氧化物酶抗体对131I治疗Graves病后甲状腺功能减退发生率的影响

目的探讨甲状腺球蛋白抗体(TGAb)和甲状腺过氧化物酶抗体(TPOAb)对131I治疗Graves病时甲状腺功能减退(简称甲低)发生率的影响。方法对接受131I治疗的198例患者按血清中甲状腺自身抗体TGAb和TPOAb是否阳性分成两组,对比两组的甲低发生率。结果患者经131I治疗后12个月复查甲状腺功能,TGAb和TPOAb阳性组甲低发生率明显高于TGAb和TPOAb阴性组(P<0.01)。结论 TGAb和TPOAb阳性可明显提高131I治疗Graves病后甲低的发生率。     

TRAb、TGAb及TPOAb检测在甲状腺疾病诊治中的价值

目的探讨促甲状腺素受体抗体(TRAb)、甲状腺球蛋白抗体(TGAb)及抗甲状腺过氧化物抗体(TPOAb)检测在甲状腺疾病诊治中的价值。方法回顾性选取2015年7年至2018年7月我院158例甲状腺疾病患者作为研究组,并选取同期我院143例健康体检者为对照组,所有受试者均行TRAb、TGAb及TPOAb检测,分析TRAb、TGAb及TPOAb检测在甲状腺疾病诊治中的价值。结果甲状腺疾病患者TRAb、TGAb及TPOAb水平均显著高于对照组(P<0.05),治疗后各甲状腺疾病患者上述指标水平均显著低于治疗前(P<0.05),治疗前后亚甲炎患者的TRAb及TPOAb水平均显著低于其他疾病(P<0.05),治疗前后桥本甲状腺炎患者TPOAb水平均显著高于其他疾病(P<0.05)。结论 TRAb、TGAb及TPOAb检测可为甲状腺疾病的诊断及预后判断提供参考依据。     

TGAb、TMAb检测在甲状腺功能亢进症131Ⅰ治疗中的意义

目的 探讨甲状腺功能亢进症(简称甲亢)经131Ⅰ治疗后甲状腺功能减退症(简称甲低)发生率与甲状腺球蛋白抗体(TGAb)、甲状腺微粒体抗体(TMAb)的关系.方法 采用放射免疫分析法测定86例甲亢患者TGAb、TMAb水平,据其分为TGAb和TMAb阳性组44例与TGAb、TMAb阴性组42例,131Ⅰ治疗半年后分析其结果与TGAb、TMAb的关系.结果 TGAb、TMAb阳性组患者治愈率61.4%(27/44),好转率4.5%(2/44),甲低率34.1%(15/44);TGAb、TMAb阴性组患者治愈率71.4%(30/42),好转率11.9%(5/42),甲低率14.3%(6/42),无效率2.4%(1/42),TGAb、TMAb阳性组治疗后甲低率明显高于TGAb、TMAb阴性组(x2=4.567,P＜0.05).结论 治疗前TGAb、TMAb测定对预测甲低发生率有参考价值.     

TGAb 和 TPOAb 水平与 Graves 病患者甲状腺功能减退的关系研究

目的：探讨血清甲状腺过氧化物抗体（TPOAb）和甲状腺球蛋白抗体（TGAb）水平与弥漫性甲状腺肿伴甲状腺功能亢进症病（Graves 病）患者131 I 治疗后甲状腺功能减退症的关系。方法选择2012年1～12月收治的Graves 病患者79例为研究对象,根据治疗前不同血清 TPOAb、TGAb 水平分为4个亚组,均接受131 I 治疗并随访2年,比较不同亚组之间随访期间甲状腺功能减退症发生率,并通过 Logistic 回归分析法分析血清 TPOAb、TGAb 水平与甲状腺功能减退症关系。结果随访2年时间,共29例患者发生甲状腺功能减退症（36.71％）,病例4组甲状腺功能减退症发生率为47.92％,显著高于病例1组,差异有统计学意义（ P ＜0.05）;Logistic 回归分析结果显示,131 I 服用剂量及治疗前血清 TPOAb、TGAb 水平是甲状腺功能减退症发生的重要危险因素（ P ＜0.05）。结论治疗前血清 TGAb和 TPOAb 水平是 Graves 病患者131 I 治疗后发生甲状腺功能减退症的重要影响因素,控制131 I 服用剂量有助于减少甲状腺功能减退症的发生。     

Prevalence of HCV antibodies in autoimmune thyroid disease

BACKGROUND AND OBJECTIVES: Auto-immune thyroid disease (AITD) has often been reported during interferon-alpha therapy for chronic viral C hepatitis (HCV) or other diseases. Recently, a high AITD prevalence has been reported in HCV independently on alpha-interferon therapy. The aim of our study is to investigate the possible relationship between AITD and HCV and HBV virus infections, and their influence on the thyroid function. MATERIAL AND METHODS: We prospectively studied 112 patients with AITD (94 women and 18 men; mean age: 49.8 +/- 14.9 yrs) and 88 patients with non-toxic goitre (NTG) (73 women and 15 men; mean age: 50.2 +/- 13.5 yrs) as controls. In all patients HCV antibodies, HBsAg and anti-HBs antibodies, TSH, FT3 and FT4 serum levels, circulating anti-thyroid-peroxidase antibodies (TPO-Ab) and anti-thyroglobulin antibodies (TG-Ab) were measured. RESULTS: HCV antibodies were positive in 11.6% of AITD patients (13/112) and in 2.3% of controls (2/88) (P < 0.05), the prevalence of HCV in the controls being similar to the expected value in the general population (about 2%). HBsAg and anti-HBs were found only in 2.6% of AITD patients (3/112) and 1.1% of controls (1/88) (P = NS), according to the expected value in the general population (about 2.5%). No difference in thyroid function was observed between positive and negative HCV subgroups. CONCLUSION: A significant association between HCV infection and AITD was found. This finding confirms that HCV, but not HBV, could be one of the environmental factors responsible for the breakdown of immunological tolerance. Therefore detection of TPO-Ab and TG-Ab in all HCV patients, independently of IFN therapy, is suggested and the utility of a screening for HCV in all AITD patients is stressed.     

抗甲状腺过氧化酶抗体与早期自然流产相关性分析

目的：分析抗甲状腺过氧化酶抗体与早期自然流产的相关性。方法：选取2013年9月～2014年12月到我院就诊的122例早期自然流产患者为病例组,以同期来我院行健康体检的60例健康女性为参照组。采用电化学发光法监测所有对象的血清甲状腺功能,包括抗甲状腺过氧化酶抗体（TPO-Ab）和抗甲状腺球蛋白抗体（TG-Ab）,分析比较两组研究对象的监测结果。结果：①病例组的TG-Ab、TPO-Ab水平均明显高于参照组（P＜0.05）;②病例组的TG-Ab阳性率（75.41％）、TPO-Ab阳性率（52.46％）、TA阳性率（50.00％）均显著高于参照组（分别为1.67％、0和1.67％）（P＜0.05）;③多元回归分析结果显示,早期自然流产与抗甲状腺过氧化酶抗体（TPO-Ab）阳性存在相关性。结论：抗甲状腺过氧化酶抗体（TPO-Ab）阳性与早期自然流产存在相关性,需做好甲状腺自身抗体检测和其他措施,降低早期自然流产的发生率。     

Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease

The aim of our study was to evaluate the diagnostic sensitivity of the new thyrotropin receptor antibody (TRAb) assays (Cosmic TRAb CT, ELISA and Yamasa DYNOtest TRAb). TRAb was positive in 43 of 44 (97.7%) untreated patients with Graves' disease by both TRAb CT and/or ELISA and NYNOtest TRAb. Thus the new TRAb assays were clearly more sensitive than the conventional assay (positivity: 85%). There was a strong positive correlation between the data obtained in TRAb CT and/or ELISA and those obtained in DYNOtest TRAb (r = 0.942, p < 0.0001). There was a significant correlation between the new TRAb and TSAb (r = 0.696, p < 0.0001). Although there was a significant correlation between the new TRAb and thyroid stimulation-blocking antibody (TSBAb), the correlation coefficient was low (r = 0.605, p < 0.0001). The increased sensitivity of the new TRAb assays for Graves' disease provides an advantage over conventional assay.     

Amiodarone-induced thyroid dysfunction: diagnostic role of free serum thyroid hormone levels and pathogenetic significance of antithyroid antibodies

Forty-six patients treated with amiodarone hydrochloride for a mean period of 41 +/- 3.5 months, with an average daily dose of 240 +/- 57 mg/day, have been studied. Thyroid function was assessed clinically and by laboratory tests, which included free-triiodothyronine (free-T3), free-thyroxine (free-T4) and thyrotropin. Antimicrosomal and antithyroglobulin antibodies were also looked for. Three patients (6.5%) were found to be hyperthyroid and two (4.3%) hypothyroid. Of the 41 clinically euthyroid patients, 19 (46.3%) showed one or more abnormalities in the thyroid function tests. In this group, only free-T4 was found significantly increased (p less than 0.05) as compared to both control populations. Antimicrosomal antibodies (titre greater than or equal to 1:1600) were present in 4 of 41 (9.7%) euthyroid patients, but not in hyper- or hypothyroid patients. There were no antithyroglobulin antibodies in any patients. Free hormone measurements have proved to significantly correlate with the clinical picture. Increases in free-T3 and free-T4 are the main features of hyperthyroidism, while a reduction in free-T4 serum level was specific for hypothyroidism. There are probably several mechanisms responsible for hyperthyroidism and some genetically controlled defects in synthesis and release of thyroid hormones might be among these. The presence of antithyroid antibodies could be due to deposits of amiodarone in the thyroid gland, with a consequent release of antigen from the follicle cell, but only in those patients with genetically determined defects in immunological surveillance could an autoimmune thyroiditis, with consequent hypothyroidism, develop.     

孕妇TPO抗体和新生儿甲状腺功能关系探讨

目的通过对孕妇甲状腺过氧化物酶抗体(TPOAb)和新生儿促甲状腺激素(TSH)的筛查,了解孕妇TPOAb是否会对新生儿甲状腺功能造成不良影响。方法选择230例甲状腺功能正常的妊娠早期孕妇作为研究对象,根据TPOAb结果分为阳性和阴性两组,比较两组孕妇甲状腺功能以及产后新生儿临床特征和TSH指标。结果 (1)在TPOAb阳性和阴性孕妇中,TSH水平差异有显著性(2χ=12.03,P<0.05);(2)两组新生儿临床特征差异无显著性(P>0.05);而TPOAb阳性组产妇的新生儿TSH水平高于TPOAb阴性组产妇的新生儿TSH水平,差异有显著性(t=4.681,P<0.05);(3)相关分析显示,孕妇TPOAb滴度和TSH水平分别与新生儿TSH水平呈正相关(r=0.201,0.209,均P<0.01)。结论 TPOAb阳性妊娠早期孕妇甲状腺功能有向亚临床甲状腺功能减退转化的趋势。孕妇TPOAb阳性可能会对新生儿甲状腺功能造成一定影响。     

孕妇妊娠早期甲状腺过氧化物酶抗体与促甲状腺激素的关系以及妊娠结局

目的探究孕妇妊娠早期甲状腺过氧化物酶抗体(TPOAb)与促甲状腺激素(TSH)的关系以及妊娠结局。方法选取2014年10月~2015年10月我院接收的60例孕周为16~24周的孕妇进行研究。血清中TSH采用免疫发光分析法测定,TPOAb采用电化学发光免疫分析法测定。记录孕妇血清中的促甲状腺激素(TSH)与抗甲状腺过氧化物酶抗体(TPOAb)水平,以及TPOAb阴性、TPOAb阳性孕妇的TSH水平,记录TPOAb阴性、TPOAb阳性孕妇的先兆流产率、先兆早产率、早产率等不良妊娠发生率。结果 60例孕妇中,TSH水平正常的孕妇28例,占46.7%,TSH水平异常的孕妇32例,占53.3%;TPOAb阳性孕妇有27例,占45.0%;TPOAb阴性孕妇有33例,占55.0%。其中TSH水平异常患者的TPOAb阳性有22例(68.75%),TSH水平正常患者的TPOAb阳性有5例(17.86%),TSH水平不同患者的TPOAb阳性发生率比较,差异明显(P0.05);根据TPOAb阳性组与阴性组孕妇血清中TSH水平得出,阳性组(27/60),阴性组(33/60),33例TPOAb阴性孕妇仅有3例TSH异常,因此,TPOAb阳性组与阴性组孕妇血清中TSH异常水平比较,差异具有统计学意义(P0.05);TPOAb阳性组产妇的先兆流产率、先兆早产率、早产率等不良妊娠发生率(40.7%)明显高于TPOAb阴性组,差异具有统计学意义(P0.05)。结论 TPOAb和TSH的检测可以提高甲状腺功能紊乱的检测率,TPOAb阳性的孕妇甲状腺紊乱显著增多,对胎儿的发育以及孕妇的生命健康意义明显,值得在临床上大力应用推广。     

Thyroid antibodies and tumor necrosis factor-alpha in patients with benign thyroid nodules treated by percutaneous ethanol injections

OBJECTIVE: Treatment of benign thyroid tumors with percutaneous ethanol injections (PEI) is an alternative to radioiodine and surgery. This procedure causes a release of large amounts of denaturated thyroglobulin within the gland which may become an autoantigen, triggering the mechanism of autoimmunization. The aim of the study was to investigate whether ethanol injections can induce increased levels of thyroid autoantibodies and tumor necrosis factor-alpha (TNF-alpha) in patients with nonfunctioning or pre-toxic thyroid nodules. MATERIAL AND METHODS: Thirty-four patients (31 F, 3 M) with single benign thyroid tumors were enrolled, 23 (20 F/3 M) with nonfunctioning nodule (group 1) and 11 (F) with pre-toxic nodule characterized by normal free thyroid hormones and low TSH (group 2). Under sonographic guidance, sterile 96% ethanol solution was injected into thyroid nodules at 2-week intervals up to a dose of 0.7-1.0 ml of ethanol per 1.0 ml nodule volume. TSH, fT4, thyroglobulin antibodies and thyroperoxidase antibodies as well as TNF-apha levels were assessed prior to alcohol administration and 3, 6, and 12 months after the end of treatment. RESULTS: PEI treatment decreased tumor volume by 75.8% in group 1 and by 80.4% in group 2, and normalized TSH level in 90.9% of patients with pre-toxic nodules. No statistically significant differences in thyroperoxidase antibodies and TNF-alpha levels were observed during the study period in both groups. Thyroglobulin antibody levels increased significantly 6 months after treatment in both groups, but returned to the baseline levels after 12 months. No significant difference in peak thyroglobulin antibody levels between the two groups was seen. CONCLUSION: PEI procedure is a safe method for treating nonfunctioning and pre-toxic thyroid nodules since this treatment reduces tumor size significantly without inducing long-lasting autoimmune reactions in the thyroid gland. Transient increase in thyroglobulin antibodies indicates that this procedure should be performed with caution in patients at risk of autoimmune diseases.     

甲状腺术后并发甲状腺危象的危险因素分析

目的：探讨除不恰当术前准备以外的易发甲状腺术后甲状腺危象的危险因素。方法：回顾性分析本院近5年收治的725例甲状腺手术患者的资料,预先设计统一的表格,收集可能的危险因素,进行影响因素分析。结果：725例甲状腺疾病患者术后共并发甲状腺危象11例,并发率为1.5%。单因素、多因素分析均显示年龄、疾病构成、合并心脏病或合并糖尿病是甲状腺术后好发甲状腺危象的独立危险因素。结论：高龄、原发病为甲状腺功能亢进症、合并心脏病或合并糖尿病是甲状腺术后除不恰当术前准备以外的易发甲状腺危象的危险因素,含有以上危险因素的患者,临床应多给予重视。